文献速递艾滋病与性传播感染病毒性肝炎

暴露前预防用药的HIV阴性男男性行为者中丙型肝炎既往暴露与发病率低:新南威尔士州扩大暴露前预防实施项目前瞻性实施研究结果

Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus-Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings From the Expanded PrEP Implementation in Communities-New South Wales Prospective Implementation Study.
PubMed 文献 · Clin Infect Dis · 2022-01-01

EPIC-NSW队列研究纳入9596名高HIV感染风险者,每日服用恩曲他滨/富马酸替诺福韦二吡呋酯预防HIV,2016至2019年报告丙型肝炎病毒(HCV)既往暴露与发病率。8658人有至少1次HCV检测结果,基线HCV既往暴露81人(0.9%,95%CI:.7-1.2),8577人中20人诊断新发感染(发病率0.2/100人年,95%CI:.1-.3/100人年)。作者结论认为该暴露前预防用药人群中HCV既往暴露与发病率均低。

要点

  • 8658名暴露前预防用药者中基线HCV既往暴露81人,占0.9%(95%CI:.7-1.2)。
  • 8577人中新发HCV感染20例,发病率0.2/100人年(95%CI:.1-.3/100人年)。
  • 新发感染者较无新发感染者年龄更大(中位41岁 vs 34岁,P=.044),基线报告甲基苯丙胺使用更多(发病率比2.7,95%CI:1.00-7.2)。

核心结论

  • 在该暴露前预防用药人群中,HCV既往暴露与发病率均低;作者认为在HCV和HIV检测与治疗水平高的情况下,该人群可实现HIV与HCV消除的双重目标。

研究设计与样本

  • EPIC-NSW为队列研究,每日口服恩曲他滨/富马酸替诺福韦二吡呋酯复方制剂用于HIV预防,从澳大利亚新南威尔士州和澳大利亚首都领地31家诊所招募9596名高HIV感染风险者,报告2016至2019年HCV既往暴露与发病率,临床试验注册号NCT02870790。

主要发现

  • 8658名(90.2%)参与者有至少1次HCV检测结果,中位年龄34岁(四分位距28-43),男性8530人(98.5%),自认男同性恋者7944人(91.8%),澳大利亚出生者占51.8%。
  • 基线检出HCV既往暴露81人(0.9%,95%CI:.7-1.2)。
  • 8577名参与者中20人诊断新发HCV感染,发病率为0.2/100人年(95%CI:.1-.3/100人年)。
  • 新发感染者较无新发感染者年龄更大(中位41岁 vs 34岁,P=.044),基线报告甲基苯丙胺使用的比例更高(发病率比2.7,95%CI:1.00-7.2)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of preexposure prophylaxis (PrEP) for the prevention of human immunodeficiency virus (HIV) has raised concerns of increased sexual risk behaviors. These behaviors may be associated with increased incidence of sexually acquired hepatitis C virus (HCV) among gay and bisexual men. METHODS: The Expanded PrEP Implementation in Communities-New South Wales (EPIC-NSW) study was a cohort study of daily coformulated tenofovir disoproxil fumarate and emtricitabine for HIV prevention. We recruited 9596 people at high risk of HIV acquisition from 31 clinics across New South Wales and the Australia Capital Territory in Australia. We report prior exposure to HCV and incidence in this cohort between 2016 and 2019. RESULTS: At least 1 HCV test result was available for 8658 (90.2%) participants. These individuals had a median age of 34 years (interquartile range, 28-43), most of whom were male (8530, 98.5%), identified as gay (7944, 91.8%), and were born in Australia (51.8%). Prior exposure to HCV was detected among 81 participants at baseline (0.9%; 95% confidence interval [CI]: .71.2). Twenty of 8577 participants were diagnosed with incident infection (rate 0.2/100 person-years [95% CI: .1-.3/100 person-years]). They were significantly older (median age 41 years vs 34 years, P = .044), and more likely to report methamphetamine use at baseline (incidence rate ratio, 2.7 [95% CI: 1.00-7.2]) than those without incident infection. CONCLUSIONS: In this population of PrEP users, HCV prior exposure and incidence were low. With high levels of HCV and HIV testing and treatment, the dual goals of HIV and HCV elimination could be achieved in this population. Clinical Trials Registration: number NCT02870790.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Amin J, Vaccher S, Templeton DJ, et al. Low Prior Exposure and Incidence of Hepatitis C in Human Immunodeficiency Virus-Negative Gay and Bisexual Men Taking Preexposure Prophylaxis (PrEP): Findings From the Expanded PrEP Implementation in Communities-New South Wales Prospective Implementation Study. Clin Infect Dis. 2022. PMID: 35352102. doi:10.1093/cid/ciac231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。